AstraZeneca to acquire biotech firm at cost of up to $1B
AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.
Health Care Roundup: Market Talk
Find insights on AstraZeneca, Incyte and more in the latest Market Talks from the health-care sector.
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
Fierce Pharma3h
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
AstraZeneca (AZN) Receives a Buy from Bernstein
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...
Fierce Biotech6h
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
FTSE 100 Live 17 March: AstraZeneca unveils £1bn deal, Qinetiq cuts guidance
Phoenix shares surge on upgraded guidance 08:26 , Graeme Evans The FTSE 100-listed shares of ...
AstraZeneca announces Imfinzi approved in European Union
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...